Background/Aim: Well-known factors for a poor prognosis in IgA nephropathy (IgAN) are hypertension, proteinuria, and renal insufficiency at the time of diagnosis. Also hypertriglyceridemia and hyperuricemia seem to play a role in the progression of IgAN. Angiotensin-converting enzyme (ACE) gene I/D polymorphism has been associated with cardiovascular diseases and with progression of IgAN. We, therefore, investigated the contribution of ACE gene I/D polymorphism in the prognosis of IgAN and its association with the other risk factors affecting the prognosis. Methods: A total of 168 patients with IgAN were followed up for 6–17 (median 11) years from renal biopsy with respect to progression of renal disease defined as elevation of serum creatinine above 125 µM (1.4 mg/dl) in men or 105 µM (1.2 mg/dl) in women and over 20% from the baseline level. In addition to serum creatinine, the urinary protein excretion was evaluated at the time of renal biopsy and at the assessment visit at the end of the follow-up period. Results: During the follow-up period, 26 (15%) patients showed progression of renal disease. Patients with ACE genotype II had a more favorable course than those with genotypes ID or DD. Although there were no significant differences among the ACE genotypes with respect to proteinuria ≧1 g/24 h at the time of renal biopsy, proteinuria ≧1 g/24 h was more frequent in patients with genotypes ID or DD than in those with genotype II at the end of the follow-up period. No associations were found between hypertension, serum lipids or serum urate, and ACE genotypes. Conclusions: Our results show that patients with ACE genotype II have a more favorable prognosis than those with genotypes ID/DD. Secondly, proteinuria (≧1 g/24 h) found in patients with genotype II at diagnosis may improve, while in patients with genotypes ID/DD it is a more constant feature.

Keywords:
Angiotensin-converting enzyme, Gene polymorphism, Glomerulonephritis, IgA nephropathy, Proteinuria
1.
D’Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;245:709–727.
2.
Packham D: Prognosis in IgA nephropathy. Nephrology 1997;3:231–235.
3.
Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34–42.
4.
Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641–644.
5.
Arbustini E, Grasso M, Fasani R, Klersy C, Diegoli M, Porcu E, Banchieri N, Fortina P, Danesino C, Specchia G: Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J 1995;74:584–591.
6.
Gardemann A, Weiss T, Schwartz O, Eberbach A, Katz N, Hehrlein FW, Tillmanns H, Waas W, Haberbosch W: Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. Circulation 1995;92:2796–2799.
7.
Huang X-H, Rantalaiho V, Wirta O, Pasternack A, Koivula T, Hiltunen TP, Nikkari T, Lehtimäki T: Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years. Metabolism 1998;47:1258–1262.
8.
Yoshida H, Mitarai T, Kawamura T, Katajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162–2169.
9.
Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rodger RS, Junor BJ, Briggs JD, Connell JM, Jardine AG: Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995;345:1540–1542.
10.
Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M: Polymorphism of the angiotensin converting enyzme gene and clinical aspects of IgA nephropathy. Clin Nephrol 1995;44:80–85.
11.
Hunley TE, Julian BA, Phillips JA III, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996;49:571–577.
12.
Tanaka R, Iijima K, Murakami R, Koide M, Nakamura H, Yoshikawa N: ACE gene polymorphism in childhood IgA nephropathy: Association with clinicopathologic findings. Am J Kidney Dis 1998;31:774–779.
13.
Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe AJ, Clarkson AR, Ponticelli C, Campise M, Mayer G, et al: No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995;26:727–731.
14.
Berthoux F, El Deeb S, Deprele C, Cecillon S, Berthoux P, Alamartine E: Polymorphism study in primary IgA nephritis (IgAN) of genes (ACE, AGT, AT1-R, eNOS) involved in arterial hypertension (abstract). J Am Soc Nephrol 1997;8:A0391.
15.
Pei Y, Scholey J, Thai K, Suzuki M, Cattran D: Association of angiotensinogen gene T235 variant with progression of immunoglobulin A nephropathy in Caucasian patients. J Clin Invest 1997;100:814–820.
16.
Mustonen J, Pasternack A: Associated diseases in IgA nephropathy; in Clarkson AR (ed): IgA Nephropathy. Boston, Nijoff, 1987, pp 47–65.
17.
Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992;20:1433.
18.
Fogart DG, Maxwell AP, Dohert C, Hughes AE, Nevin NC: ACE gene typing. Lancet 1994;343:851.
19.
Cox DR, Oakes D: Analysis of Survival Data. London, Chapman and Hall, 1984.
20.
Alamartine E, Sabatier J-C, Guérin C, Berliet J-M, Berthoux F: Prognostic factors in mesangial IgA glomerulonephritis. An extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12–19.
21.
Huang X-H, Rantalaiho V, Wirta O, Pasternack A, Koivula T, Hiltunen T, Nikkari T, Lehtimäki T: Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM. Hum Genet 1998;102:372–378.
22.
Rigat B, Humber C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–1346.
23.
Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993;3:1531–1540.
24.
Huang X-O, Rantalaiho V, Wirta O, Pasternack A, Hiltunen TP, Koivula T, Malminiemi K, Nikkari T, Lehtimäki T: Angiotensin-converting enzyme insertion/deletion polymorphism and diabetic albuminuria in patients with NIDDM followed up for 9 years. Nephron 1998;80:17–24.
25.
Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991;39:1267–1273.
26.
Hernandez E, Toledo T, Alamo C, Mon C, Rodicio JL, Praga M: Elevation of von Willebrand factor levels in patients with IgA nephropathy: Effect of ACE inhibition. Am J Kidney Dis 1997;30:397–403.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.